New hope for Hard-to-Treat cancers? early trial tests revumenib
NCT ID NCT05731947
First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 15 times
Summary
This early-phase study tested a drug called revumenib in 42 adults with colorectal cancer or other solid tumors that had worsened after at least one prior treatment. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors or slow cancer growth. The study is now complete, and results will help decide if further testing is worthwhile.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Honor Health Research Institute
Scottsdale, Arizona, 85258, United States
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
Manhattan, New York, 10065, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.